Business Context and Reporting Period
This Form 6-K filing by Bioblast Pharma Ltd. (also referenced as Enlivex Ltd. in metadata) covers the month of December 2018. The report documents the results of the Annual and Extraordinary General Meeting of Shareholders held on December 27, 2018.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a corporate governance report rather than a financial statement.
Material Changes
Shareholders approved all agenda items as originally proposed. These items were previously detailed in Exhibits 99.1 and 99.2 of a Form 6-K submitted on December 6, 2018. No other material financial changes are disclosed in this specific text.
Guidance, Outlook, and Risks
The filing incorporates this report by reference into registration statements on Form F-3 (File No. 333-206032) and Form S-8 (File Nos. 333-203114 and 333-210459). The document does not contain specific management commentary on future guidance, operational risks, contingencies, or unusual items beyond the shareholder meeting outcomes.
Investor Verification Checklist
- Review Exhibits 99.1 and 99.2 from the December 6, 2018 Form 6-K to understand the specific agenda items approved by shareholders.
- Verify the status of the registration statements on Form F-3 and Form S-8 referenced in the filing.
- Confirm the current leadership structure, noting Dr. Dalia Megiddo is listed as Interim Chief Executive Officer.
- Check subsequent filings for the detailed financial results for the period ending December 27, 2018, as they are absent here.